Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S.

for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti. Bysanti is a new chemical entity ...

Vanda Pharmaceuticals Inc. (Vanda) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysantitm ...

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute ...

The stress of becoming homeless along with cannabis use may have triggered the first schizophrenic episode in a young man who ...

The latest issues of three American Psychiatric Association journals, The American Journal of Psychiatry, Psychiatric Services and The American Journal of Psychotherapy  are now available online.

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance ...

Learn more about whether Intra-Cellular Therapies, Inc. or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Us Weekly and the harris project's 'The Missing Issue' takes a look back at Aaron Carter's candid quotes about his addiction ...

Medical directors welcome the idea of regulators placing more responsibility in their hands, but changes will require more ...